Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma

Table 3 Expression of EMMPRIN protein categorized by pathological variables.

Variables	EMMPRIN		P
	-	+
Serum AFP level
≤25 ng/mL (n = 22)	12	10	0.242
>25 ng/mL (n = 29)	11	18
HBsAg
Positive (n = 16)	9	7	0.284
Negative (n = 35)	14	21
Microsatellite nodule
Absent (n = 31)	13	18	0.576
Present (n = 20)	10	10
Tumor size
≤3 cm (n = 18)	9	9	0.607
>3 cm (n = 33)	14	19
Cirrhosis
Absent (n = 36)	18	18	0.281
Present (n = 15)	5	10
Necrosis
Absent (n = 24)	11	13	0.992
Present (n = 27)	12	15
Portal vein thrombosis
Absent (n = 37)	15	22	0.292
Present (n = 14)	8	6
Differentiation
Well (n = 35)	16	19	0.897
Low (n = 16)	7	9
Extra-hepatic metastasis
Absent (n = 41)	19	22	0.721
Present (n = 10)	4	6